Eli Lilly & Company’s stock is one of the most active to buy according to Wall Street analysts after positive Phase 3 trial results for its obesity treatment. UBS reaffirms a Buy rating and $895 price target, with peak sales forecasted at $15 billion pending full data presentation at EASD.

Orforglipron shows efficacy in obesity and diabetes patients, comparable to Novo Nordisk’s Wegovy. UBS sees a more optimistic commercial outlook than expected, supporting its peak sales forecast for Eli Lilly & Company’s medication. Full data presentation at EASD will provide comprehensive safety and efficacy information.

Eli Lilly & Company is a major global pharmaceutical company founded in 1876, known for developing, manufacturing, and distributing a wide range of drugs. While LLY shows investment potential, some AI stocks offer greater upside potential and less downside risk, particularly related to Trump-era tariffs and the onshoring trend.

Read more at Yahoo Finance: UBS Sees $15 Billion Sales Potential for Eli Lilly’s (LLY) Obesity Treatment Orforglipron